Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Mansfield C, Sutphin J, Boeri M. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question. Health Econ. 2020 Oct;29(10):1307-15. doi: 10.1002/hec.4124
Heidenreich S, Watson V, Ryan M, Phimister E. Decision heuristic or preference? Attribute non-attendance in discrete choice problems. Health Econ. 2018 Jan;27(1):157-71. doi: 10.1002/hec.3524
Tsuchiya A, Watson V. Re-thinking “the different perspectives that can be used when eliciting preferences in health". Health Econ. 2017 Dec;26(12):e103-7. doi: 10.1002/hec.3480
Krucien N, Watson V, Ryan M. Is best-worst scaling suitable for health state valuation? A comparison with discrete choice experiments. Health Econ. 2017 Dec;26(12):e1-e16. doi: 10.1002/hec.3459
Watson V, Becker F, de Bekker-Grob E. Discrete choice experiment response rates: a meta-analysis. Health Econ. 2017 Jun;26(6):810-7. doi: 10.1002/hec.3354
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988
Williams V, Rousculp MD, Price M, Coles T, Therrien MA, Griffin J, Hollis K, Toback S. Elementary school-located influenza vaccine programs: key stakeholder experiences from initiation to continuation. J Sch Nurs. 2012 Aug 1;28(4):256-67.
Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, Houser KA, Keyes V. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. 2012 Jun;21(6):633-52.
Ryan M, Watson V. Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Health Econ. 2009 Apr;18(4):389-401. doi: 10.1002/hec.1364
Ryan M, Watson V, Entwistle V. Rationalising the 'irrational': a think aloud study of discrete choice experiment responses. Health Econ. 2009 Mar;18(3):321-36. doi: 10.1002/hec.1369
Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005 Nov 1;14(11):1133-50.